Seeking Alpha
11 Jun 2026, 07:22 UTC · 3h ago
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
11 Jun 2026, 07:22 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Darovasertib + crizotinib met the mPFS primary endpoint in 1st-line HLA*A2-negative mUM. — Meeting a primary clinical endpoint is a critical success milestone that significantly increases the probability of regulatory approval.
+0.80IDEAYA is moving toward an RTOR NDA Accelerated Approval submission filing for darovasertib. — The transition to an NDA filing indicates a clear path toward commercialization and potential revenue generation.
+0.60Upcoming catalysts include label expansion data for HLA*A2-positive mUM and neoadjuvant/adjuvant melanoma updates. — Label expansion increases the total addressable market (TAM), providing further upside potential for the asset.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The company expects to complete the darovasertib NDA filing submission in H2 2026. — While a clear timeline is helpful, the distant date (2026) limits the immediate short-term price catalyst effect.
Which stocks this story touches
The company maintains a Strong Buy rating following positive clinical data and progress toward an NDA submission.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
13h ago
